Literature DB >> 1130851

The effect of dextran on the lysability of ex vivo thrombi.

M Aberg, S E Bergentz, U Hedner.   

Abstract

The lysability was determined of thrombi formed in Chandler tubes before and after infusion of 500 ml dextran 70 to patients undergoing cholecystectomy. 125I-labelled fibrinogen was given the day before operation. Following incubation of the thrombi formed in plasmin, radioactivity remaining in the thrombi and released to the supernatant was determined, as well as fibrinolytic degradation products in the supernatant, using an immunoelectrophoretic method. The dextran infusion was found to increase the radioactivity released from the thrombi to the supernatant from 15.5 plus or minus 7.6% to a maximum of 27.3 plus or minus 8.2% four hours after the infusion (P less than 0.001). A corresponding significant rise of the FDP concentration in the supernatant from 16.8 mug/ml to 44.1 mug/ml was found at the same time. After 24 hours the radioactivity had returned to initial values. The results indicate that dextran infused into patients during surgery increases the lysability of thrombi. It is suggested that this finding at least partly explains the antithrombotic effect of dextran.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1130851      PMCID: PMC1343859          DOI: 10.1097/00000658-197503000-00016

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  19 in total

1.  IN VIVO BEHAVIOR OF I-FIBRINOGEN.

Authors:  A S McFarlane
Journal:  J Clin Invest       Date:  1963-03       Impact factor: 14.808

2.  Prevention of thrombosis after pelvic surgery by British dextran 70.

Authors:  J Bonnar; J Walsh
Journal:  Lancet       Date:  1972-03-18       Impact factor: 79.321

3.  Effect of dextran infusion on the adenosine diphosphate induced adhesiveness and the spreading capacity of human blood platelets.

Authors:  S Bygdeman; R Eliasson; B Gullbring
Journal:  Thromb Diath Haemorrh       Date:  1966-05-15

4.  Separation and estimation split "products" of fibrinogen and fibrin in human serum.

Authors:  J E Niléhn
Journal:  Thromb Diath Haemorrh       Date:  1967-12-31

5.  [Influence of dextran on fibrin polymerization].

Authors:  W Krause; D Heene; H G Lasch
Journal:  Klin Wochenschr       Date:  1971-12-15

6.  Dextran in prophylaxis of thrombosis in fractures of the hip.

Authors:  A Ahlberg; G Nylander; B Robertson; S Cronberg; I M Nilsson
Journal:  Acta Chir Scand Suppl       Date:  1968

7.  Acceleration of fibrin polymerization by dextran and ficoll. Interaction with calcium and plasma proteins.

Authors:  U Abildgaard
Journal:  Scand J Clin Lab Invest       Date:  1966       Impact factor: 1.713

8.  The antithrombotic effect of dextran.

Authors:  U F Gruber; S E Bergentz
Journal:  J Surg Res       Date:  1966-09       Impact factor: 2.192

9.  Suppressive effect of dextran on platelet adhesiveness.

Authors:  S Cronberg; B Robertson; I M Nilsson; J E Niléhn
Journal:  Thromb Diath Haemorrh       Date:  1966-12-01

10.  In vitro thrombotic coagulation of the blood; a method for producing a thrombus.

Authors:  A B CHANDLER
Journal:  Lab Invest       Date:  1958 Mar-Apr       Impact factor: 5.662

View more
  5 in total

1.  Dextran in the prophylaxis of pulmonary embolism.

Authors:  S E Bergentz
Journal:  World J Surg       Date:  1978-01       Impact factor: 3.352

Review 2.  Prophylaxis of venous thromboembolism.

Authors:  V V Kakkar; M D Stringer
Journal:  World J Surg       Date:  1990 Sep-Oct       Impact factor: 3.352

Review 3.  Antithrombotic drugs: part II.

Authors:  A S Gallus; J Hirsh
Journal:  Drugs       Date:  1976       Impact factor: 9.546

4.  Effect of dextran on factor VIII (antihemophilic factor) and platelet function.

Authors:  M Aberg; U Hedner; S E Bergentz
Journal:  Ann Surg       Date:  1979-02       Impact factor: 12.969

Review 5.  Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis.

Authors:  G P Clagett; J S Reisch
Journal:  Ann Surg       Date:  1988-08       Impact factor: 12.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.